ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

Senate Committee Directs NCI To Conduct Research To Eliminate Barriers To Enrollment On Clinical Trials.

July 6, 2007

In Brief: Baque Heads Cancer Control Science Programs; Joftes, Davignon T Retire; Schepartz Returns

September 29, 1989

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

CCIRC Report Suggests Ways To Enhance Role Of Surgeons

July 22, 1977

Ohio State Breaks Ground For $1 Billion Expansion Of Medical Center, Cancer Hospital

June 18, 2010